Skip to content

A Novel Completely Bioabsorbable Occluder for Ventricular Septal Defect Closure in a first-in-man clinical trial

A Novel Completely Bioabsorbable Occluder for Ventricular Septal Defect Closure in a first-in-man clinical trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022845
Enrollment
Unknown
Registered
2019-04-28
Start date
2017-12-25
Completion date
Unknown
Last updated
2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular septal defect

Interventions

Cases:Completely Bioabsorbable Occluder for Ventricular Septal Defect

Sponsors

Fuwai Yunnan Cardiovascular Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5.7 Years to 10 Years

Inclusion criteria

Inclusion criteria: 1. Subjects and/or their legal guardians will be informed of the nature of this study and agree to participate in this clinical trial in accordance with all terms of this study.Signed the informed consent approved by the ethics committee, agreed to accept the postoperative treatment program, and completed the follow-up and related examinations as required by the follow-up; 2. Age =6 months, weight more than 5 kg, male or non-pregnant women; 3. Perimembranous ventricular septal defect (VSD) echocardiography showed increased cardiac load, simple VSD with hemodynamic significance, diameter =3 mm, meningioma < 14 mm, no meningioma < 10 mm; 4. Distance between the edge of defect and the right aortic valve is more than 2mm, no aortic valve prolapse or moderate aortic regurgitation; Echocardiography showed the defect at 9~12 points on the short axis five-chamber view of the great vessels.

Exclusion criteria

Exclusion criteria: 1. Irreversible pulmonary vascular disease;Severe pulmonary hypertension with bidirectional shunt; 2. Bleeding disorders or known clotting disorders(including heparin-induced thrombocytopenia),contraindications to antiplatelet therapy, or rejection of transfusions; 3. Sepsis or severe infection within 1 month prior to occlusion; 4. Patients with thrombosis at the occluder placement and venous thrombosis at the catheter insertion site; 5. Cardiac malformation dependent on ventricular septal defect.

Design outcomes

Primary

MeasureTime frame
blocking success rate;

Secondary

MeasureTime frame
Surgical technique success rate;

Countries

China

Contacts

Public ContactXiangbin Pan

Fuwai Yunnan Cardiovascular Hospital

xiangbin428@hotmail.com+86 13811763898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026